Alnylam Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
675 W Kendall St # A, Cambridge, Massach...Phone Number
(617) 551-8200Website
www.alnylam.comRevenue
$4.8 BillionStock Symbol
ALNYIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
2
1
1
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemRead more
Alnylam Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alnylam Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Alnylam Pharmaceuticals had a recent Job posting/layoffs
Alnylam Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Alnylam Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Alnylam Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Alnylam Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Alnylam Pharmaceuticals
Funding: Get notified immidiatlly once Alnylam Pharmaceuticals has new funding data
Check if Alnylam Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Alnylam Pharmaceuticals
Find more new buyers
Compare Similar Companies to Alnylam Pharmaceuticals
Compare insights from companies similar to Alnylam Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alnylam Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alnylam Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals financials insights
Gather financial insights about Alnylam Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2004
Stock Offering
$30.2M
2011
Corporate Investment
$10M
2020
Private Equity
$2B
Other Financing Round
$150M
Alnylam Pharmaceuticals Tech Stack
A closer look at the technologies used by Alnylam Pharmaceuticals
Most Recent Scoops
Person-Based
Product Development, Pharmaceuticals
Person-Based
Muthiah Manoharan will participate as a speaker at ST Pharm RNA innovation symposium on September 8.
Events
Project
Contracts
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Alnylam Pharmaceuticals News & Media
Singapore is the first ASEAN country to provide government subsidy for eligible patients receiving vutrisiran for transthyretin amyloidosis
"From September 2026 – eligible patients receiving vutrisiran will receive government subsidies of up to 75%[1],[2]" "HELIOS-A and B provide strong clinical evidence supporting improved patient outcomes" SINGAPORE, Sept. 1, 2026 /PRNewswire/ -- Medison Pharma (Medison), the creator of a first-of-its-kind unified global commercialisation platform for breakthrough therapies, today announced that from September 1st, 2026, vutrisiran has been recommended for inclusion in the Medication Assistance FuKessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
RADNOR, Pa., Aug. 15, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on behalf of investors who purchased or acquired Alnylam Pharmaceuticals, Inc. securities and experienced significant financial losses.ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES, Aug. 4, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ: ALNY) for violations of...Alnylam Pharmaceuticals (ALNY), Inceptive Form $2B Partnership to Advance RNAi Drug Discovery
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the most promising long-term stocks to buy according to analysts. On June 3, Alnylam and Inceptive Nucleics, which builds foundation models of life, announced a collaboration valued at up to $2 billion to accelerate the discovery of RNAi therapeutics. It combines Alnylam’s extensive RNAi platform and two decades […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alnylam Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatme... Read More
